English
|
正體中文
|
简体中文
|
全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 882361 線上人數 : 686
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
搜尋範圍
全部NHRI
分子與基因醫學研究所
生技與藥物研究所
生醫工程與奈米醫學研究所
免疫醫學研究中心
神經及精神醫學研究中心
細胞及系統醫學研究所
感染症與疫苗研究所
群體健康科學研究所
癌症研究所
國家環境醫學研究所
國家蚊媒傳染病防治研究中心
高齡醫學暨健康福祉研究中心
論壇
生醫資源中心
研究生培育合作學程
核心儀器設施中心
病理核心實驗室
實驗動物中心
行政管理部門
圖書館
查詢小技巧:
您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
進階搜尋
主頁
‧
登入
‧
上傳
‧
說明
‧
關於NHRI
‧
管理
國家衛生研究院 NHRI
>
作者相關文件
資料載入中.....
類別瀏覽
正在載入社群分類, 請稍候....
年代瀏覽
正在載入年代分類, 請稍候....
"Macarulla, T"的相關文件
回到依作者瀏覽
顯示 14 項.
類別
日期
題名
關聯
檔案
[陳立宗] 會議論文/會議摘要
2016-05
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
-
[陳立宗] 會議論文/會議摘要
2016-10
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
-
[陳立宗] 期刊論文
2018-11-07
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
-
[陳立宗] 會議論文/會議摘要
2021-05
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)
-
[陳立宗] 期刊論文
2018-01
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
-
[陳立宗] 會議論文/會議摘要
2016-02
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
-
[陳立宗] 期刊論文
2019-07-28
Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer
-
[陳立宗] 期刊論文
2016-02
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
-
[陳立宗] 期刊論文
2019-05
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
-
[陳立宗] 會議論文/會議摘要
2016-10
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
-
[陳立宗] 會議論文/會議摘要
2016-02
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
-
[陳立宗] 會議論文/會議摘要
2015-01
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
-
[陳立宗] 會議論文/會議摘要
2017-02
Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO
-
[陳立宗] 期刊論文
2021-01
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1
-
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
回饋